These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22614184)

  • 1. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer.
    Kendler DB; Vaisman F; Corbo R; Martins R; Vaisman M
    Clin Nucl Med; 2012 Jun; 37(6):545-9. PubMed ID: 22614184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of different clinical and pathological variables in patients with differentiated thyroid cancer on successful ablation for 3700 MBq (131)I: a single Egyptian institutional experience over 14 years.
    Husseini MA
    Ann Nucl Med; 2016 Aug; 30(7):468-76. PubMed ID: 27194041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage.
    Zhang Y; Hua W; Zhang X; Peng J; Liang J; Gao Z
    Nucl Med Commun; 2018 May; 39(5):405-410. PubMed ID: 29557849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study.
    Long Y; Jin J; Zhang W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(10):1204-1214. PubMed ID: 38192150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma.
    Tamilia M; Al-Kahtani N; Rochon L; Hier MP; Payne RJ; Holcroft CA; Black MJ
    Nucl Med Commun; 2011 Mar; 32(3):212-20. PubMed ID: 21191314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan.
    Giovanella L; Suriano S; Ceriani L; Verburg FA
    Clin Nucl Med; 2011 Feb; 36(2):109-12. PubMed ID: 21220971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
    Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
    Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
    Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
    J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of initial stimulation thyroglobulins and staging system by revised ATA guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation.
    Kim MH; Ko SH; Bae JS; Lim DJ; Baek KH; Lee JM; Kang MI; Cha BY
    Clin Nucl Med; 2012 Nov; 37(11):1069-74. PubMed ID: 22996253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
    Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
    Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin.
    Zhang Y; Liang J; Yang X; Yang K; Lin Y
    Nucl Med Commun; 2015 Jun; 36(6):553-9. PubMed ID: 25793928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of fractionated doses of iodine-131 for ablation of thyroid remnants.
    Wang SJ; Liu TJ
    Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.